 Drug Approval
"Drug Approval" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Process that is gone through in order for a drug to receive approval by a government regulatory agency. This includes any required pre-clinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance of the drug.
| Descriptor ID |
D017277
|
| MeSH Number(s) |
E05.337.300 I01.880.604.605.250.250
|
| Concept/Terms |
Drug Approval- Drug Approval
- Approval, Drug
- Approvals, Drug
- Drug Approvals
- Food and Drug Administration Drug Approval
Drug Approval Process- Drug Approval Process
- Approval Process, Drug
- Approval Processes, Drug
- Drug Approval Processes
- Process, Drug Approval
- Processes, Drug Approval
New Drug Approval- New Drug Approval
- Approval, New Drug
- Approvals, New Drug
- Drug Approval, New
- Drug Approvals, New
- New Drug Approvals
|
Below are MeSH descriptors whose meaning is more general than "Drug Approval".
Below are MeSH descriptors whose meaning is more specific than "Drug Approval".
This graph shows the total number of publications written about "Drug Approval" by people in this website by year, and whether "Drug Approval" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 | | 2000 | 0 | 1 | 1 | | 2002 | 1 | 0 | 1 | | 2003 | 0 | 1 | 1 | | 2006 | 2 | 2 | 4 | | 2008 | 2 | 1 | 3 | | 2009 | 3 | 0 | 3 | | 2010 | 1 | 0 | 1 | | 2011 | 2 | 0 | 2 | | 2012 | 2 | 5 | 7 | | 2014 | 0 | 2 | 2 | | 2015 | 2 | 5 | 7 | | 2016 | 0 | 1 | 1 | | 2017 | 0 | 2 | 2 | | 2018 | 1 | 6 | 7 | | 2019 | 5 | 3 | 8 | | 2020 | 0 | 2 | 2 | | 2021 | 1 | 8 | 9 | | 2022 | 0 | 1 | 1 | | 2023 | 0 | 1 | 1 | | 2024 | 1 | 2 | 3 | | 2025 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Approval" by people in Profiles.
-
Elder C, Pellinen J, Terman SW. The Epilepsy Drug Pipeline: Update on Near-to-Market Therapies. Semin Neurol. 2025 Apr; 45(2):287-297.
-
McMahon C, Raddi MG, Mohan S, Santini V. New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes. Am Soc Clin Oncol Educ Book. 2025 Jun; 45(3):e473654.
-
Walsh C. Genetic Implications for Cancer Management: The Changing Landscape of Poly (ADP-ribose) Polymerase Inhibitor Indications in the Treatment of Ovarian Cancer. Clin Obstet Gynecol. 2024 Dec 01; 67(4):711-719.
-
Costa E, Girotti S, Mathieu C, Castellani C, Ross JS, Taylor-Cousar JL, Leufkens HGM. Differential times of submission and approval of CFTR modulators for the treatment of Cystic Fibrosis in the United States and the European Union. J Cyst Fibros. 2025 Jan; 24(1):125-132.
-
Casale TB, Fiocchi A, Greenhawt M. A practical guide for implementing omalizumab therapy for food allergy. J Allergy Clin Immunol. 2024 Jun; 153(6):1510-1517.
-
Garg SK, Snell-Bergeon J, Kaur G, Beatson C. Challenges of GLP Analog Use for People with Type 1 Diabetes: Issues with Prior Approvals and Tips for Safer Use. Diabetes Technol Ther. 2024 Jun; 26(6):363-366.
-
Costa E, Girotti S, van den Ham HA, Cipolli M, van der Ent CK, Taylor-Cousar JL, Leufkens HGM. Traits, trends and hits of orphan drug designations in cystic fibrosis. J Cyst Fibros. 2023 09; 22(5):949-957.
-
DiStefano MJ, Alexander GC, Polsky D, Anderson GF. Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey. J Am Geriatr Soc. 2022 06; 70(6):1685-1694.
-
Woodworth KR, Moulia D, Collins JP, Hadler SC, Jones JM, Reddy SC, Chamberland M, Campos-Outcalt D, Morgan RL, Brooks O, Talbot HK, Lee GM, Bell BP, Daley MF, Mbaeyi S, Dooling K, Oliver SE. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5-11 Years - United States, November 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 12; 70(45):1579-1583.
-
Mbaeyi S, Oliver SE, Collins JP, Godfrey M, Goswami ND, Hadler SC, Jones J, Moline H, Moulia D, Reddy S, Schmit K, Wallace M, Chamberland M, Campos-Outcalt D, Morgan RL, Bell BP, Brooks O, Kotton C, Talbot HK, Lee G, Daley MF, Dooling K. The Advisory Committee on Immunization Practices' Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines - United States, 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1545-1552.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|